Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

iStem's safety profile, together with trends suggesting meaningful improvement in functional measures, illustrates the potential of this therapy in this area and supports further clinical study of MultiStem for the treatment of heart disease."

    During the first 24 hours following MultiStem administration, patients were assessed for infusion-related toxicity and other acute adverse events. Subsequently, patients were evaluated for cardiac adverse events. The primary endpoints for the study were the assessment of acute adverse events during the first 24 hours following administration, post-acute adverse events up to 30 days, and catheter-related events.

    The administration of MultiStem was found to be well tolerated at all dose levels evaluated. There were no dose limiting toxicities associated with the administration of MultiStem. Immediately following dosing, there were no clinically significant changes to vital signs or evidence of allergic reaction associated with MultiStem administration. Over the 30-day post-acute observation period, no infusional toxicities or clinically significant cardiac adverse events deemed to be definitely related to MultiStem occurred.

    MultiStem had a favorable safety profile over the four-month period following treatment. There was no dose dependent effect of MultiStem on adverse events (AEs) and generally AEs were mild to moderate in nature. Overall, there were several observed AEs characterized as potentially related to MultiStem or catheter delivery. These were generally mild to moderate in nature and were not dose dependent.

    Heart Function

    While the primary objective of this phase I study is to evaluate the safety of MultiStem administered to AMI patients, echocardiogram data are being collected and evaluated for evidence of
    '/>"/>


SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: ... and expertly narrows down the mass of product choices ... terminals. , First, select the working environment, then ... instead) and define the accuracy – it’s really that ... the list to models that fit best with the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 As part ... numerous projects in the MENA region during 2014 with ... a preferred provider agreement with DZS to manage our ... region,” said Global VP of R&D and President of ... developed excellent operational practices with a focus on utilizing ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... Conference at 10:30 a.m. ET on Tuesday, January,8, 2008. ... available in the,Investor Relations section of the Medarex Web ... presentation will be available following the event., About ...
... PARK, N.C., Jan. 3 Chimerix, Inc., a,biotechnology ... Neil Frazer, M.B., Ch.B., FRCA, FFPM has joined ... joining Chimerix, Dr. Frazer served as the Chief ... (previously,Biocure Medical) where he was responsible for the ...
... (Nasdaq: ONXX ) today announced that it ... January 7, at 11:30 a.m.,Pacific Time. Interested parties ... http://www.metameetings.com/webcasts/jpmorgan/healthcare08 , It is recommended ... order to,register and download any necessary software. For ...
Cached Biology Technology:Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... over a 35 year period in which the human ... humans on declining animal numbers. This decline matters because ... crustaceans, slugs and worms bring to our day-to-day lives, ... nutrient cycling, water filtration and human health. , The ... UCL, Stanford and UCSB, focused on the demise of ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... of seven tropical forests around the world has revealed ... less common trees. The landmark study, conducted by 33 ... 27 issue of the journal Science, conclusively demonstrates that ... , Helene Muller-Landau, an assistant professor of ecology in ...
... Mellon University have discovered that our ears use the ... from babbling brooks to wailing babies. These results represent ... is encoded for transmission to the brain, according to ... "News and Views" editorial in the Feb. 23 issue ...
... of Pittsburgh Professor of Anthropology Jeffrey H. Schwartz and ... Jan. 30 in the New Anatomist journal, shows that ... to Schwartz's theory of evolution, originally explained in his ... of Species (John Wiley & Sons, 2000). , In ...
Cached Biology News:Underdogs in the understory: Study suggests nature favors rarer trees 2Carnegie Mellon scientists show brain uses optimal code for sound 2Carnegie Mellon scientists show brain uses optimal code for sound 3Pitt professor's theory of evolution gets boost from cell research 2Pitt professor's theory of evolution gets boost from cell research 3
ID clarifier: platform...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... is used for vertical electrophoresis applications. The cell accommodates ... L of running buffer. It includes the PROTEAN II ... kit, which contains accessories for use with 2.0 mm ... 2 sets of 20 x 20 cm glass plates, ...
Biology Products: